# Cab la PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cab-la

> The next catalyst for cab la, sponsored by GSK plc (GSK), is its topline data readout, Mar to Jun 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | cab la |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [HIV Infections](https://sec-api.dev/indications/hiv-infections) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 9, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: HIV Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06741397 (A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor ViiV Healthcare." https://clinicaltrials.gov/study/NCT06741397

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: HIV Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06741397 (A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor ViiV Healthcare." https://clinicaltrials.gov/study/NCT06741397

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: HIV Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06134362 (Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor ViiV Healthcare." https://clinicaltrials.gov/study/NCT06134362

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: HIV Infections.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06134362 (Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-03-14 (ESTIMATED); Lead Sponsor ViiV Healthcare." https://clinicaltrials.gov/study/NCT06134362

## Same indication

- [Cab la + rpv la](https://sec-api.dev/pdufa/cab-la-rpv-la) (GSK)
- [Vocabria (cabotegravir sodium)](https://sec-api.dev/pdufa/cabotegravir) (GSK)
- [Dtg/3tc](https://sec-api.dev/pdufa/dtg-3tc) (GSK)
- [Yeztugo® (lenacapavir)](https://sec-api.dev/pdufa/lenacapavir) (GILD)
- [VH4524184](https://sec-api.dev/pdufa/vh4524184) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cab-la.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cab la PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cab-la

```bibtex
@misc{secapidev_pdufa_cab_la_20261116,
  title        = {Cab la PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cab-la}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cab_la_20261116","title":"Cab la PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cab-la","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
